Krystal Biotech (KRYS) News Today

Krystal Biotech, Inc. (NASDAQ: KRYS) shares have risen amid a flurry of analyst activity and clinical updates. Investors are reacting to strengthened buy ratings, strategic pipeline shifts toward inhaled KB707, and mixed signals from price-target revisions.

• Positive Sentiment: 10 analysts maintain a consensus “Buy” rating on KRYS after reviewing the company’s fundamentals and clinical pipeline. A Glimpse Into The Expert Outlook On Krystal Biotech Through 10 Analysts
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and set a $240 price target, implying 59.5% upside from current levels. Read More
• Positive Sentiment: Inhaled KB707 for NSCLC achieved a 36% objective response rate in heavily pretreated patients, and an FDA End-of-Phase-2 meeting is scheduled for October 2025, highlighting the program’s momentum. Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update
• Neutral Sentiment: Enrollment in the OPAL-1 intratumoral KB707 trial has been paused as Krystal shifts focus to the inhaled formulation, indicating a strategic reprioritization. Krystal Biotech says prioritizing inhaled KB707, pauses enrollment in OPAL-1
• Neutral Sentiment: Krystal provided a detailed update on inhaled KB707 ahead of its FDA meeting, emphasizing safety, tolerability, and ongoing enrollment in the KYANITE-1 study. Krystal Biotech Provides Development Update on Inhaled KB707 for Non-Small Cell Lung Cancer Treatment
• Negative Sentiment: Chardan Capital lowered its price target from $219 to $216, though it maintained a “Buy” rating, suggesting limited near-term upside. Krystal Biotech price target lowered to $216 from $219 at Chardan
• Negative Sentiment: Krystal cut its melanoma viral immunotherapy trial amid FDA pathway uncertainty, potentially delaying future data reads. Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway